ijms-logo

Journal Browser

Journal Browser

Current Research for Castration Resistance Prostate Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 28 June 2024 | Viewed by 2233

Special Issue Editor


E-Mail Website
Guest Editor
TRePCa, Université Paris Est Créteil, F-94010 Creteil, France
Interests: prostate cancer; CRPC; extracellular vesicles; tumoral heterogeneity; biomarkers; therapeutic resistance

Special Issue Information

Dear Colleagues,

Prostate cancer (CaP) is the second most common cancer in terms of incidence and the fifth most common cancer death in men worldwide. Treatment approaches and prognosis for CaP depend on its stage at diagnosis. Initially, CaP is treated with androgen deprivation therapy with a good initial response but followed by inevitable relapse. In recent years, new therapies based on inhibition of the androgen receptor pathway or taxanes have been developed, in particular to combat the phenomenon of castration resistance. However, the emergence of resistance clearly limits their benefits and their use. Not all mechanisms leading to castration resistance and treatment resistance in CaP have been elucidated. Similarly, these resistances demonstrate the potential need for the development of new therapies.

The Special Issue focuses on new advances in the mechanisms of castration resistance and therapeutic resistance in prostate cancer and in new treatments for CRPC.

Dr. Virginie Firlej
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • castration-resistant prostate cancer
  • therapy resistance
  • biomarkers
  • androgen receptor
  • new therapies
  • tumor microenvironment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

26 pages, 12954 KiB  
Article
Dysbindin Domain-Containing 1 in Prostate Cancer: New Insights into Bioinformatic Validation of Molecular and Immunological Features
by Van Thi Ngoc Tram, Hoang Dang Khoa Ta, Gangga Anuraga, Phan Vu Thuy Dung, Do Thi Minh Xuan, Sanskriti Dey, Chih-Yang Wang and Yen-Nien Liu
Int. J. Mol. Sci. 2023, 24(15), 11930; https://doi.org/10.3390/ijms241511930 - 25 Jul 2023
Viewed by 1970
Abstract
Prostate cancer (PCa) is one of the most prevalent cancers in men, yet its pathogenic pathways remain poorly understood. Transcriptomics and high-throughput sequencing can help uncover cancer diagnostic targets and understand biological circuits. Using prostate adenocarcinoma (PRAD) datasets of various web-based applications (GEPIA, [...] Read more.
Prostate cancer (PCa) is one of the most prevalent cancers in men, yet its pathogenic pathways remain poorly understood. Transcriptomics and high-throughput sequencing can help uncover cancer diagnostic targets and understand biological circuits. Using prostate adenocarcinoma (PRAD) datasets of various web-based applications (GEPIA, UALCAN, cBioPortal, SR Plot, hTFtarget, Genome Browser, and MetaCore), we found that upregulated dysbindin domain-containing 1 (DBNDD1) expression in primary prostate tumors was strongly correlated with pathways involving the cell cycle, mitotic in KEGG, WIKI, and REACTOME database, and transcription factor-binding sites with the DBNDD1 gene in prostate samples. DBNDD1 gene expression was influenced by sample type, cancer stage, and promoter methylation levels of different cancers, such as PRAD, liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD). Regulation of glycogen synthase kinase (GSK)-3β in bipolar disorder and ATP/ITP/GTP/XTP/TTP/CTP/UTP metabolic pathways was closely correlated with the DBNDD1 gene and its co-expressed genes in PCa. DBNDD1 gene expression was positively associated with immune infiltration of B cells, Myeloid-derived suppressor cell (MDSC), M2 macrophages, andneutrophil, whereas negatively correlated with CD8+ T cells, T follicular helper cells, M1 macrophages, and NK cells in PCa. These findings suggest that DBNDD1 may serve as a viable prognostic marker not only for early-stage PCa but also for immunotherapies. Full article
(This article belongs to the Special Issue Current Research for Castration Resistance Prostate Cancer)
Show Figures

Figure 1

Back to TopTop